Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE-ON: GTX-104 vs Oral Nimodipine in aSAH
NCT05995405Phase 3Active, not recruiting
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of GTX-104 in aneurysmal subarachnoid hemorrhage (SAH), sponsored by Grace Therapeutics, Inc.. Started Oct 2023; status: active, not recruiting.
02
Drugs
GTX-104
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05995405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995405.